The invention provides a system for the transdermal delivery of buprenorphine, including an a-hydroxy acid. The transdermal therapeutic system (TTS) allows the continuous delivery of buprenorphine in a therapeutically effective dose over a period of at least three days, and is distinguished in particular by a polymer matrix in which the active ingredient is present in a physically stabilized form.